The remission clinic approach to halt the progression of kidney disease

Journal of Nephrology

Volumn 24, Issue 3, 2011, Pages 274-281

[No Author Info available]

Author keywords

ACE inhibitor; Angiotensin ii receptor blocker; Blood pressure; Chronic kidney disease; Proteinuria; Remission clinic

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BENAZEPIL PLUS VALSARTAN; BENAZEPRIL; DIHYDROPYRIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOSARTAN; LOSARTAN PLUS RAMIPRIL; MINOXIDIL; RAMIPRIL; TELMISARTAN; THIAZIDE DIURETIC AGENT; TRANDOLAPRIL; UNCLASSIFIED DRUG; VALSARTAN;

ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL PRACTICE; COMBINATION CHEMOTHERAPY; DIABETIC NEPHROPATHY; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG DOSE TITRATION; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; GLOMERULUS FILTRATION RATE; HUMAN; HYPERKALEMIA; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY FUNCTION; LIFESTYLE MODIFICATION; MICROALBUMINURIA; MONOTHERAPY; NONHUMAN; PATIENT MONITORING; PREDICTION; PROTEINURIA; REMISSION; RENAL PROTECTION; RENAL REPLACEMENT THERAPY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SMOKING CESSATION; SODIUM RESTRICTION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD PRESSURE; CHRONIC DISEASE; CLINICAL PROTOCOLS; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; ITALY; KIDNEY DISEASES; KIDNEY FAILURE, CHRONIC; LIFE STYLE; RENIN-ANGIOTENSIN SYSTEM; SMOKING CESSATION;

EID: 79955937056     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: 10.5301/JN.2011.7763     Document Type: Article

References (37)

1. United States Renal Data System (USRDS), Annual Data Report 2007: 92.
2. Abbate M, Zoja C, Remuzzi G. How does proteinuria cause progressive renal damage? J Am Soc Nephrol. 2006;17: 2974-2984.
3. Remuzzi G, Benigni A, Remuzzi A. Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J Clin Invest. 2006;116: 288-296.
4. Ruggenenti P, Perna A, Mosconi L, Pisoni R, Remuzzi G; Gruppo Italiano di Studi Epidemiol. Urinary protein excretion rate is the best independent predictor of ESRF in nondiabetic proteinuric chronic nephropathies. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Kidney Int.1998;53: 1209-1216.
5. Macconi D, Abbate M, Morigi M, et al. Permselective dysfunction of podocyte-podocyte contact upon angiotensin II unravels the molecular target for renoprotective intervention. Am J Pathol. 2006;168: 1073-1085.
6. Remuzzi G, Bertani T. Pathophysiology of progressive nephropathies. N Engl J Med. 1998;339: 1448-1456.
7. Cravedi P, Ruggenenti P, Remuzzi G. Intensified inhibition of renin-angiotensin system: a way to improve renal protection? Curr Hypertens Rep. 2007;9: 430-436.
8. Campbell RC, Ruggenenti P, Remuzzi G. Halting the progression of chronic nephropathy. J Am Soc Nephrol. 2002;13(Suppl 3): S190-S195.
9. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet. 1997;349: 1857-1863.
10. Zoja C, Corna D, Camozzi D, et al. How to fully protect the kidney in a severe model of progressive nephropathy: a multidrug approach. J Am Soc Nephrol. 2002;13: 2898-2908.
11. Cao Z, Bonnet F, Davis B, Allen TJ, Cooper ME. Additive hypotensive and anti-albuminuric effects of angiotensin-converting enzyme inhibition and angiotensin receptor antagonism in diabetic spontaneously hypertensive rats. Clin Sci (Lond). 2001;100: 591-599.
12. Russo D, Minutolo R, Pisani A, et al. Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy. Am J Kidney Dis. 2001;38: 18-25.
13. Mogensen CE, Neldam S, Tikkanen I, et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ. 2000;321: 1440-1444.
14. Taal MW, Brenner BM. Combination ACEI and ARB therapy: additional benefit in renoprotection? Curr Opin Nephrol Hypertens. 2002;11: 377-381.
15. Catapano F, Chiodini P, De Nicola L, et al. Antiproteinuric response to dual blockade of the renin-angiotensin system in primary glomerulonephritis: meta-analysis and metaregression. Am J Kidney Dis. 2008;52: 475-485.
16. Campbell R, Sangalli F, Perticucci E, et al. Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies. Kidney Int. 2003;63: 1094-1103.
17. Ruggenenti P, Schieppati A, Remuzzi G. Progression, remission, regression of chronic renal diseases. Lancet. 2001;357: 1601-1608.
18. Mann JF, Schmieder RE, McQueen M, et al; ONTARGET investigators. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet. 2008;372:547-553.
19. Ruggenenti P, Remuzzi G. Proteinuria: Is the ONTARGET renal substudy actually off target? Nat Rev Nephrol. 2009;5: 436-437.
20. Maschio G, Alberti D, Janin G, et al; The Angiotensin-Converting- Enzyme Inhibition in Progressive Renal Insufficiency Study Group. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med. 1996;334: 939-945.
21. Locatelli F, Carbarns IR, Maschio G, et al; The Angiotensin- Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. Long-term progression of chronic renal insufficiency in the AIPRI Extension Study. Kidney Int Suppl. 1997;63: S63-S66.
22. Ruggenenti P, Cravedi P, Remuzzi G. Proteinuria: increased angiotensin-receptor blocking is not the first option. Nat Rev Nephrol. 2009;5: 367-368.
23. Takaichi K, Takemoto F, Ubara Y, Mori Y. Analysis of factors causing hyperkalemia. Intern Med. 2007;46: 823-829.
24. Davies DF, Shock NW. Age changes in glomerular filtration rate, effective renal plasma flow, and tubular excretory capacity in adult males. J Clin Invest. 1950;29:496-507.
25. Sandhu S, Wiebe N, Fried LF, Tonelli M. Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol. 2006;17: 2006-2016.
26. Conley J, Olafsson A, Djamali A. Do statins delay the incidence of ESRD in diabetic patients with moderate CKD? J Nephrol. 2010;23: 321-327.
27. Ruggenenti P, Perna A, Tonelli M, et al. Effects of add-on fluvastatin therapy in patients with chronic proteinuric nephropathy on dual renin-angiotensin system blockade: The ESPLANADE Trial. Clin J Am Soc Nephrol. 2010;5: 1928-1938.
28. Ruggenenti P, Perticucci E, Cravedi P, et al. Role of remission clinics in the longitudinal treatment of CKD. J Am Soc Nephrol. 2008;19: 1213-1224.
29. Bianchi S, Bigazzi R, Caiazza A, Campese VM. A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am J Kidney Dis. 2003;41: 565-570.
30. Heeg JE, de Jong PE, van der Hem GK, de Zeeuw D. Efficacyand variability of the antiproteinuric effect of ACE inhibition by lisinopril. Kidney Int. 1989;36: 272-279.
31. Bianchi S, Bigazzi R, Campese VM. Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney Int. 2006;70: 2116-2123.
32. Perico N, Benigni A, Remuzzi G. Present and future drug treatments for chronic kidney diseases: evolving targets in renoprotection. Nat Rev Drug Discov. 2008;7: 936-953.
33. Egan CG, Pontremoli R. Role of the fixed-dose combination lercanidipine-enalapril in renal protection. J Nephrol. 2011 Jan 24 (Epub ahead of print).
34. Perico N, Amuchastegui SC, Colosio V, Sonzogni G, Bertani T, Remuzzi G. Evidence that an angiotensin-converting enzyme inhibitor has a different effect on glomerular injury according to the different phase of the disease at which the treatment is started. J Am Soc Nephrol. 1994;5: 1139-1146.
35. Ruggenenti P, Fassi A, Ilieva AP, et al; Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators. Preventing microalbuminuria in type 2 diabetes. N Engl J Med. 2004;351: 1941-1951.
36. Codreanu I, Perico N, Sharma SK, Schieppati A, Remuzzi G. Prevention programmes of progressive renal disease in developing nations. Nephrology (Carlton). 2006;11: 321-328.
37. Yusuf S, Pais P, Afzal R, et al; Indian Polycap Study (TIPS). Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial. Lancet. 2009;373: 1341- 1351.